Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of L-NAME and Midodrine to Increase MAP

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Spinal Cord Injured Subjects:~* chronic spinal cord injury (1 year post injury) with a seated MAP of 65mmHg (almost all individuals with tetraplegia demonstrate this)~* Male or female with an age of 18 - 65 years~Control Subjects:~* Male or female with an age of 18 - 65 years~Exclusion Criteria:~Spinal Cord Injured Subjects:~* acute illness~* cardiovascular disease~* renal disease~* medications that affect the cardiovascular system~Control Subjects:~* acute illness~* cardiovascular disease~* renal disease~* medications that affect the cardiovascular system

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Midodrine (Type: EXPERIMENTAL): A drug to treat low blood pressure.
- L-Name (Type: EXPERIMENTAL): L-Name: A non-selective inhibitor of nitric oxide synthase and placebo. It has been used experimentally to induce hypertension.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo: A pill with an inactive substance that looks like the study drug.

Based on this trial design, predict the completion outcome and termination type (if applicable).